FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.

Survival analysis in the anthracycline-treated cohort based on the log-rank test indicated that FOXC1 expression ( P = 0.038) and tumor size ( P = 0.006) could slightly better differentiate between the two survival groups in the analyzed sample collection, whereas differences in groups classified by menopausal status, nodal status, and tumor differentiation did not reach statistical significance (Tables 3 , 4 ).

also in 111,027 other papers